IN2012DN05143A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05143A
IN2012DN05143A IN5143DEN2012A IN2012DN05143A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A IN 5143DEN2012 A IN5143DEN2012 A IN 5143DEN2012A IN 2012DN05143 A IN2012DN05143 A IN 2012DN05143A
Authority
IN
India
Prior art keywords
present
glioma
tbs40
nfl
peptide
Prior art date
Application number
Other languages
English (en)
Inventor
Joel Eyer
Alan Peterson
Julien Balzeau
Raphael Berges
Original Assignee
Univ Angers
Inst Nat Sante Rech Med
Univ Mcgill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Angers, Inst Nat Sante Rech Med, Univ Mcgill filed Critical Univ Angers
Publication of IN2012DN05143A publication Critical patent/IN2012DN05143A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039Coumarin dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
IN5143DEN2012 2009-12-14 2010-12-14 IN2012DN05143A (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28620709P 2009-12-14 2009-12-14
EP09306227A EP2332560A1 (en) 2009-12-14 2009-12-14 Use of a neurofilament peptide for the treatment of glioma
PCT/EP2010/069663 WO2011073207A1 (en) 2009-12-14 2010-12-14 Use of a neurofilament peptide for the treatment of glioma

Publications (1)

Publication Number Publication Date
IN2012DN05143A true IN2012DN05143A (enExample) 2015-10-23

Family

ID=42133636

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5143DEN2012 IN2012DN05143A (enExample) 2009-12-14 2010-12-14

Country Status (7)

Country Link
US (2) US9446092B2 (enExample)
EP (2) EP2332560A1 (enExample)
JP (1) JP5806679B2 (enExample)
CN (1) CN102821777B (enExample)
CA (1) CA2784091C (enExample)
IN (1) IN2012DN05143A (enExample)
WO (1) WO2011073207A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire
EP2959913A1 (en) * 2014-06-23 2015-12-30 Universite D'angers Use of a neurofilament peptide for targeting neural stem cells
JP6612063B2 (ja) * 2015-06-11 2019-11-27 国立大学法人滋賀医科大学 悪性神経膠腫分子標的ペプチド
US10550388B2 (en) * 2017-08-15 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Targeting pleiotrophin signaling to limit high-grade glioma invasion
CN110133288A (zh) * 2018-03-13 2019-08-16 首都医科大学附属北京地坛医院 神经丝蛋白轻链在梅毒血液检测中的应用
EP3863686A1 (en) * 2018-10-12 2021-08-18 Advanced Accelerator Applications International S.A. Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
CN112824427B (zh) * 2019-11-18 2022-06-24 杨小骏 一种抑制胶质瘤的短肽及其应用
EP4593865A1 (en) * 2022-09-30 2025-08-06 Gliocure Pharmaceutical composition comprising nfl-tbs40-63peptide, variants or salts thereof and alanine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2869909B1 (fr) * 2004-05-04 2007-12-21 Univ Angers Peptide capable d'inhiber la polymerisation de la tubuline et son utilisation pour inhiber la proliferation cellulaire

Also Published As

Publication number Publication date
EP2512499B1 (en) 2015-09-16
US20130004429A1 (en) 2013-01-03
US20170000846A1 (en) 2017-01-05
CA2784091C (en) 2020-08-11
US9446092B2 (en) 2016-09-20
EP2332560A1 (en) 2011-06-15
CN102821777B (zh) 2014-12-17
CN102821777A (zh) 2012-12-12
EP2512499A1 (en) 2012-10-24
CA2784091A1 (en) 2011-06-23
WO2011073207A1 (en) 2011-06-23
JP5806679B2 (ja) 2015-11-10
JP2013513646A (ja) 2013-04-22

Similar Documents

Publication Publication Date Title
IN2012DN05143A (enExample)
JO2931B1 (en) Double-substituted phthalazin compounds as antagonists of the cell-specific factor pathway
MX2015007997A (es) Inhibidores de histona desmetilasa.
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
MX2012003770A (es) Metodos para la modulacion de autofagia a traves de la modulacion de productos de genes que aumentan la autofagia.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
NO20076401L (no) Diarylhydantoinforbindelser
MX347913B (es) Ciclopropilaminas como inhibidores de desmetilasa 1 especifica de lisina.
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008005954A3 (en) Tryphostin-analogs for the treatment of cell proliferative diseases
MX2009008461A (es) Variantes geneticas que contribuyen a riesgo de cancer de prostata.
EP3106168A3 (en) Targeting micrornas mir-409-5p, mir-379 and mir-154* to treat prostate cancer bone metastasis and drug resistant lung cancer
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2009011346A (es) Tapentadol para tratamiento de dolor con artritis.
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
TN2009000303A1 (en) Iron-hydrocarbon complex compounds
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
WO2008144507A3 (en) Spirooxindole inhibitors of aurora kinase
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
GB0718878D0 (en) Photodynamic Theraphy and diagnosis
MX2011004979A (es) N-cadherina:blanco para diagnosis y terapia de cancer.
MX2010006331A (es) Hidantoinas sustituidas como inhibidores de cinasa mek.